European Biotech Investment Trends

Exploring the valuation differences between European and US biotech companies, the shift towards later-stage products, challenges in attracting new investors, the rise of extension rounds, and the increasing acquisitions by big pharma. Speculating on the future outlook with potential IPOs, increased investor sentiment, and sustained investment in the European biotech scene.